Details of the Drug Combination

General Information of Drug Combination (ID: DCZU0QS)

Drug Combination Name
Entrectinib Entrectinib
Indication
Disease Entry Status REF
Solid Tumor Phase 1 [1]
Component Drugs Entrectinib   DMMPTLH Entrectinib   DMMPTLH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Entrectinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Approved [2]
Colorectal cancer 2B91.Z Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Mammary analogue secretory carcinoma 2C60 Phase 1 [5]
Neuroblastoma 2D11.2 Phase 1 [3]
Entrectinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [2]
NT-3 growth factor receptor (TrkC) TTXABCW NTRK3_HUMAN Inhibitor [2]
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [2]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [2]
BDNF/NT-3 growth factors receptor (TrkB) TTKN7QR NTRK2_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Entrectinib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Entrectinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Approved [2]
Colorectal cancer 2B91.Z Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Mammary analogue secretory carcinoma 2C60 Phase 1 [5]
Neuroblastoma 2D11.2 Phase 1 [3]
Entrectinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [2]
NT-3 growth factor receptor (TrkC) TTXABCW NTRK3_HUMAN Inhibitor [2]
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [2]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [2]
BDNF/NT-3 growth factors receptor (TrkB) TTKN7QR NTRK2_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Entrectinib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03961100) A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04589845) Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. U.S. National Institutes of Health.
5 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
6 Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-1483.